Engqungqutheleni ye-ASCO ka-2018, imiphumela yocwaningo lwe-chemotherapy yadonsa ukunaka okukhulu. Ucwaningo luye lwabonisa ukuthi i-chemotherapy emisha ingakwazi ukwelapha ngempumelelo umdlavuza we-pancreatic owaziwa ngokuthi "inkosi yomdlavuza". Kulo mdlavuza onesimo esibi kakhulu, le chemotherapy ingandisa impilo yesiguli kuze kube yizinyanga ezingama-20!
Ocwaningweni lomtholampilo olubizwa nge-PRODIGE 24 / CCTG PA.6, abacwaningi baqashe inani elikhulu leziguli ezine-non-metastatic pancreatic duct adenocarcinoma (PDAC), okuphinde kube wumdlavuza we-pancreatic ovame kakhulu, obalwa ku-90% wazo zonke izimo. %. Lezi ziguli zihlinzwe ukuze kususwe isimila. Emasontweni amathathu nambili emva kokuhlinzwa, iziguli ezingama-3 zazihlukaniswe ngezikhathi zaba ngamaqembu amabili, iqembu elilodwa lathola ukwelashwa kwe-gemcitabine (gemcitabine), elinye iqembu lathola ukwelashwa okusha ngamakhemikhali mFOLFIRINOX (modified FOLFIRINOX). Lesi sakamuva siqukethe izingxenye ezine ezihlukene zamakhemikhali, kufaka phakathi i-oxaliplatin, leucovorin, irinotecan, ne-12-fluorouracil.
Ucwaningo lukhombise ukuthi ngokulandela okuphakathi kwezinyanga ezingama-33.6, ukusinda okungenasifo kweziguli eqenjini le-mFOLFIRINOX kwakuphakeme kakhulu kunaleso seqembu le-gemcitabine (izinyanga ezingama-21.6 nezinyanga eziyi-12.8). Mayelana nokusinda okuphelele okuphakathi, okwedlule kuphakeme kakhulu kunezinyanga ezingama-20 ezedlule (izinyanga ezingama-54.4-izinyanga ezingama-35.0). Ngezinzuzo ezengeziwe zokusinda, imiphumela emibi ye-chemotherapy nayo ingalawulwa.
Ngokwecebo, abacwaningi bazoqhubeka nokuhlola isikhathi esingcono kakhulu sokwelashwa ngamakhemikhali ukuze baqonde ukuthi iziguli zingathola yini ukwelashwa ngamakhemikhali ngaphambi kokuhlinzwa ukuze zinciphise isimila, ngaleyo ndlela zinciphise ubungozi besimila i-micrometastasis nokwandisa amathuba okuthi isimila sisuswe ngokuphelele ukuhlinzwa. Silangazelele ukuzwa izindaba ezinhle eziningi ngalokhu kwelashwa futhi sivumele iziguli ezinomdlavuza we-pancreatic zibone ithemba.
